Michael Unterhalt

LMU Klinikum — Germany

Medicine · Health Sciences

48h-index10.8kcitations258works10.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(200), Chronic Lymphocytic Leukemia Research(100), Viral-associated cancers and disorders(74), Acute Myeloid Leukemia Research(42), CNS Lymphoma Diagnosis and Treatment(28)

Publications258 total

<i>Erratum</i> to: “Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance”
Haematologica·2025Open Access
EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort
Blood·2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020
Haematologica·2025Open Access
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment
BMC Cancer·2025Open Access
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
Haematologica·2025· 1 citedOpen Access
133 | LONG‐TERM SURVIVAL TRENDS IN ADVANCED‐STAGE MANTLE CELL LYMPHOMA: A POOLED ANALYSIS OF SIX RANDOMIZED PHASE III TRIALS FROM 1996 TO 2020
Hematological Oncology·2025· 1 citedOpen Access
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIAL
Hematological Oncology·2025· 1 citedOpen Access
Abstract CT225: AARON: An ongoing open-label phase I/II study of relatlimab (anti-LAG-3) with nivolumab (anti-PD-1) in combination with azacitidine ± venetoclax for the treatment of patients with relapsed/refractory and non-fit patients with newly diagnosed acute myeloid leukemia - Interim analysis
Cancer Research·2025· 4 cited
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
Blood Cancer Journal·2025· 3 citedOpen Access
Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
Blood·2024· 9 cited
Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
Blood·2024· 18 cited
Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III
Blood·2024· 1 citedOpen Access
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
The Lancet·2024· 106 citedOpen Access
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
Leukemia·2024· 8 citedOpen Access
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
Annals of Hematology·2024· 1 citedOpen Access
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma - a randomized, open-label phase III trial of the European mantle cell lymphoma network
Research Square (Research Square)·2023Open Access
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Journal of Clinical Oncology·2023· 29 citedOpen Access
Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials
Blood·2023· 9 cited
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
Annals of Hematology·2023Open Access
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Leukemia·2023· 48 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Wolfgang Hiddemann(37), Martin Dreyling(33), Eva Hoster(32), Wolfram Klapper(23), Christiane Pott(12), Olivier Hermine(11), Hanneke C. Kluin‐Nelemans(9), Jan Walewski(9), Catherine Thiéblemont(9), Vincent Ribrag(9), Bernd Metzner(8), Bernhard Wörmann(8), German Ott(8), Stephan Stilgenbauer(8), Roswitha Forstpointner(8), Michael Kneba(8), Michael Pfreundschuh(7), Michael Hallek(7), Christian Buske(7), Andreas Rosenwald(6)